Bioresorbable vs Metallic Occluders for Transcatheter Atrial Septal Defect Closure

Are bioresorbable occluders noninferior to metallic devices for transcatheter atrial septal defect (ASD) closure while exhibiting evidence of biodegradation?In this multicenter randomized noninferiority trial including 230 participants with secundum ASD, a bioresorbable occluder demonstrated a comparable 6-month ASD closure success rate (96.5% vs 97.4% with a metallic occluder) and achieved near-complete degradation (approximately 99.8%) at 2 years.A bioresorbable occluder is noninferior to a metallic occluder for ASD closure, with near-complete degradation by 2 years, offering a valuable transcatheter option.

Corresponding Author: Xiangbin Pan, MD, PhD, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, 528 N Shahe Rd, Kunming 650102, China (panxiangbin@fuwaihospital.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.